FDA Approves Eflapegrastism-xnst Injection for Adult Patients with Non-Myeloid Malignancies
September 16th 2022Eflapegrastism-xnst injection (Rolvedon, Spectrum Pharmaceuticals) is indicated to lower the incidence of infection, as demonstrated by febrile neutropenia, in adult patients with non-myeloid malignancies.
Read More
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis
September 14th 2022ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Read More